Company Profile

Industry Sector: Drug discovery

Company Overview:
Acelot has developed innovative technology for lead identification and lead optimization. The technology is based on graph-based modeling of chemical compounds and has shown to be superior and complementary to existing methods deployed in the industry.

Target Market(s):
Pharmaceuticals of all sizes.

Key Value Drivers

Technology*:
Our unique graph-based mining software supports similarity queries and significance queries that can be used for finding all compounds containing a topological chemical fragment similar to a given one and all fragments that are significant in a given collection of compounds.

Competitive Advantage:
Our topological characterization improves the current fingerprint-based technology by being sensitive to the spatial arrangement of atoms, bonds, and functional groups. We are currently conducting assays for identifying possible hits to the beta-secretase target.

Plan & Strategy:
1. Partner with drug development effort at a pharmaceutical.
2. Offer services on the Internet.
3. Produce new leads.

*Technology funded by the National Institute of Mental Health and being commercialized under the NIH-CAP

Management

Leadership:
Ambuj Singh, President

Scientific Advisory Board:
Gilbert Rishton, CSUCI and ex-Amgen

Product Pipeline

1. **FragmentFinder**: Finds all chemical compounds containing a given topological fragment. Tested on a collection of over a million compounds.
2. **SimFragmentFinder**: Finds all chemical compounds that contain a topological fragment similar to the given one. Tested on a collection of over a million compounds.
3. **SigFragmentFinder**: Finds all topological fragments occurring at a significance level much higher than random in a given collection. Tested on collections of chemical compounds as well as protein-ligand complexes.